A similar pseudo-dormant and reversible drug-tolerant phenotype have also been reported in other oncogenic contexts, such as glioblastoma [63,64], BRAF-mutant melanoma [65,66,67], colorectal cancers [59,68,69], breast cancers [70], or pancreatic cancer [71], treated either with targeted therapies or chemotherapies. The gene discussed is BRAF; the disease is colorectal cancer.